Sensorion partners with Pasteur Institute on gene therapy for hearing lossPublished: May 28, 2019
Biopharmaceutical company Sensorion has entered into a license agreement with Paris-based Pasteur Institute to develop gene therapies for hearing loss.
Sensorion is specialized in developing novel therapies to treat inner ear diseases such as hearing loss, tinnitus and vertigo. With the new partnership with the Pasteur Institute, the company intends to enter the gene therapy sector.
The new research partnership framework agreement will grant Sensorion an option to obtain exclusive licenses to develop and market drug candidates in gene therapy coming from collaborative projects, for treating monogenic hearing disorders including Otoferlin & Usher Type 1.
The collaboration was initially announced in November 2018 and since then the companies were working together to reach a partnership framework agreement.
Prof. Christine Petit at the Genetics and Physiology of the Hearing Unit of Institut Pasteur will lead the research. Sensorion currently has two Phase 2 products being evaluated in clinical trials: Seliforant (SENS-111) under investigation for acute unilateral vestibulopathy and Arazasetron for sudden sensorineural hearing loss (SSNHL).
Prof. Petit commented: “I am particularly pleased by this agreement signed between Institut Pasteur and Sensorion. It will allow us to transform our scientific progress into innovations for the benefit of patients, whether it is by contributing to create new diagnostic tools, improving patients’ healthcare pathway or developing curative treatments for hearing disorders”.
Source: Sensorion Announces the Signature of a Partnership Framework Agreement with Institut Pasteur on Gene Therapy Programs Targeting Hearing Loss; Press Release